Blood Glucose Determinations Differ in Plasma and Serum
|
By LabMedica International staff writers Posted on 05 Jul 2012 |
|
Blood glucose determination is one of the most common clinical diagnostic tests and accurate and precise measurement of blood glucose is of great importance in the diagnosis and management of diabetes.
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automated Coagulation Analyzer
Hemolumi H6
POC Immunoassay Analyzer
Procise DX
Latest Clinical Chem. News
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Channels
Molecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read more
Pathology
view channel
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
